Actively Recruiting
Evaluating Double Plasma Cytokine Adsorption With Low-Dose Plasma Exchange Versus Plasma Exchange Alone in Treating Acute-on-Chronic Liver Failure and Sepsis
Led by Third Affiliated Hospital, Sun Yat-Sen University · Updated on 2026-09-11
192
Participants Needed
1
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of a double plasma cytokine adsorption system combined with sequential low-dose plasma exchange DPCASLPE in patients who have acute-on-chronic liver failure ACLF complicated by sepsis. The study focuses on whether this therapy can improve survival rates and reduce inflammation, as well as its impact on organ function scores and cytokine removal efficiency. Participants are randomly assigned to two groups. One group receives standard medical treatment plus two sessions of DPCASLPE followed by a session of plasma exchange PE. The other group receives standard treatment and three sessions of plasma exchange alone. Treatments are given every other day, with assessments before and after each session. During the study, participants undergo evaluations of survival rates at 4 and 12 weeks, as well as repeated measurements of organ function scores like APACHE II, SOFA, MELD, and COSSH-ACLF II at multiple time points. The study also measures cytokine and lactate adsorption rates. Follow-up visits occur at 1, 2, 3, 4, and 12 weeks after treatment to monitor patient progress and safety.
CONDITIONS
Brief Title
Efficacy and Safety of Cytokine Adsorption and Plasma Exchange in Patients With ACLF and Sepsis
Research Team
L
Liang Peng, Doctor
W
Wenxiong Xu, Doctor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here